Pembrolizumab in Refractory Advanced Esophageal Cancer

NCT02971956 PHASE2 COMPLETED Results posted

This research study is studying a targeted therapy as a possible treatment for advanced esophageal cancer. The study intervention involved in this study is: -Pembrolizumab

Details

Lead sponsor	Dana-Farber Cancer Institute
Phase	PHASE2
Status	COMPLETED
Enrolment	49
Start date	Wed Jan 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed May 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Esophageal Cancer
• Squamous Cell Esophagus Cancer
• Adenocarcinoma Esophagus

Interventions

• Pembrolizumab

Countries

United States